144
Views
14
CrossRef citations to date
0
Altmetric
Original Research

A meta-analysis of data associating DRD4 gene polymorphisms with schizophrenia

, , , &
Pages 153-164 | Published online: 03 Jan 2018

Abstract

To explore the association between DRD4 polymorphisms and schizophrenia risk, a meta-analysis was carried out with 41 case–control articles. Specifically, we included 28 articles (5,735 cases and 5,278 controls) that pertained to the 48 bp variable number tandem repeat (VNTR) polymorphism, nine articles (1,517 cases and 1,746 controls) that corresponded to the 12 bp tandem repeat (TR), six articles (1,912 cases and 1,836 controls) that addressed the 120 bp TR, 10 articles (2,927 cases and 2,938 controls) that entailed the −521 C>T polymorphism, six articles (1,735 cases and 1,724 controls) that pertained to the −616 C>G polymorphism, and four articles (1,191 cases and 1,215 controls) that involved the −376 C>T polymorphism. Pooled analysis, subgroup analysis, and sensitivity analysis were performed, and the data were visualized by means of forest and funnel plots. Results of pooled analysis indicated that the −521 CC variant (Pz=0.009, odds ratio [OR] =1.218, 95% confidence interval [CI] =1.050–1.413) and genotype L/L (ie, long allele) of the 120 bp TR were risk factors of schizophrenia (Pz=0.004, OR =1.275, 95% CI =1.081–1.504). The 48 bp VNTR, the 12 bp TR, the −616 C>G polymorphism, and the −376 C>T polymorphism were not associated with schizophrenia. Additional research is warranted to explore the association between polymorphisms of DRD4 and schizophrenia risk.

Introduction

Schizophrenia is a chronic, severe mental disorder with a tremendously variable clinical presentation. Results of studies in which schizophrenia occurrence was evaluated among twins or children who were adopted have shown that this disease results from an interaction of genetics and environmental factors.Citation1 Specifically, schizophrenia is a multigene disease with a heritability of 60%–70%.Citation2 Although the pathogenesis and etiology of schizophrenia are not understood fully,Citation3 a large body of evidence has indicated that dopamine dysfunction is involved in the occurrence of this disease.Citation4Citation6

Dopamine is an endogenous neurotransmitter that primarily functions by binding to dopamine receptors, which have five types. The D4 receptor has attracted attention in the field of schizophrenia research. In postmortem brain striatum of patients with schizophrenia, the density of D4 receptor was significantly higher than in brain tissues of unaffected patients; in contrast, the density of D2 and D3 receptors remained modest.Citation7 This upregulation of D4 receptor has been shown to be related to the disease rather than to pharmacological effects of treatment.Citation8 The pharmacological characteristics of D4 resemble those of D2 and D3, but the affinity of D4 for clozapine is an order of magnitude higher.Citation9 Hence, DRD4 (chromosome 11p15.5) is a potential susceptibility gene for schizophrenia.Citation10

The SZGene database is a viable resource for ascertaining the risk of schizophrenia.Citation11,Citation12 Other investigators have determined that the −521 C>T and 120 bp tandem repeat (TR) polymorphisms in DRD4 are associated with nominally significant summary odds ratios (ORs) as risk factors for schizophrenia (P=0.003 and 0.005, respectively).Citation11 However, despite a great deal of research, an association between DRD4 polymorphisms and schizophrenia risk remains debatable.

TRs in DRD4 include a 48 bp variable number TR (VNTR), a 12 bp TR, and a 120 bp TR. The 48 bp VNTR is located in the third exon of DRD4 and encodes a sequence of 16 amino acids in the region of the third cytoplasmic loop. Polymorphisms in the 48 bp VNTR were found to differ in the recruitment of cellular cAMP.Citation13 The 12 bp TR (rs4646983) is located in the first exon of DRD4, which corresponds to the N terminus of the gene product. Variants of the 12 bp TR modify an N-terminal glycosylation site, which affects expression levels of the membrane protein.Citation14 The 120 bp TR is located 1.2 kb upstream from the initiation codon, and polymorphisms at this site affect transcriptional efficiency.Citation15 Some researchers noted that the 120 bp TR was associated with attention-deficit hyperactivity disorder (ADHD)Citation16,Citation17 and schizophrenia.Citation18 However, Tsutsumi et alCitation19 demonstrated that the 120 bp TR was not related to the risk of schizophrenia.

The −521 C>T polymorphism (rs1800955), located in the promoter region of DRD4, has been shown to be associated with novelty seekingCitation20,Citation21 and schizophrenia.Citation22 Mitsuyasu et al suggested that the −521C variant could be a risk factor for schizophrenia among female patients.Citation23 However, other investigators found no relationship between −521 C>T and schizophrenia.Citation24 The −616 C>G (rs747302) and the −376 C>T (rs916455) polymorphisms are located in the promoter region of DRD4; these variants have not been associated conclusively with schizophrenia risk. A pooled analysis of data regarding polymorphisms in DRD4 and schizophrenia risk is warranted.

Meta-analyses are proven tools for ascertaining associations of gene polymorphisms with disease.Citation25Citation27 Several meta-analyses previously have addressed the potential associations between DRD4 polymorphisms and schizophrenia risk.Citation28Citation31 However, the authors of these studies examined just one polymorphic locusCitation28 or did not include the latest data.Citation31 Herein, we describe the results of our meta-analysis of the association between DRD4 and schizophrenia risk.

Materials and methods

Literature searches

The SZGene, PubMed, and China National Knowledge Infrastructure (CNKI) databases were searched with the keywords “schizophrenia” and “DRD4”. Reference lists from relevant articles also were screened to identify additional studies.

Inclusion criteria and exclusion criteria

Studies with the following features were included in the meta-analysis: 1) case–control design; 2) involved patients with schizophrenia; 3) presented relevant data for case and control groups (eg, allele/genotype frequencies, sample size, ethnicity, schizophrenia diagnostic criteria, and control group source); 4) removed duplicate sample data; and 5) published before September 1, 2017. Studies were excluded for the following reasons: 1) no control group; 2) no usable genotype frequency data (attempts were made to contact authors via email for these data); and 3) duplicate reported sample data.

Statistical analysis

A meta-analysis was carried out using Stata Version 10.0 (StataCorp LP, College Station, TX, USA). The P-value of Hardy–Weinberg equilibrium (PHWE) was calculated for the control groups. ORs and 95% confidence intervals (CIs) were calculated to evaluate the strength of the associations. Under a random model,Citation32,Citation33 associations between DRD4 and the risk of schizophrenia were analyzed. A random model took into account population differences and heterogeneity among studies.Citation25,Citation34 Pairwise differences between genotypes (AA vs aa, Aa vs aa, and AA vs Aa [A being the risk factor]) were used to determine a suitable genetic model.Citation35

The heterogeneity of the studies was determined by Cochran’s chi-square-based Q-statistic test.Citation36 The degree of heterogeneity was expressed as ICitation2 and was divided into low (ICitation2<25%), medium (ICitation2~50%), and high (ICitation2>75%) heterogeneity groups.Citation37 ICitation2>50% was regarded as indicating substantial heterogeneity.Citation38 Publication bias was calculated using Egger’s test and was represented as a funnel plot in which the standard error of log(OR) of each study was plotted against its log(OR). A sensitivity analysis was conducted to test the impact of removing each single study on the pooled result. Statistical power was calculated by means of the PS program, as described previously.Citation39,Citation40 P-values corresponding to association, heterogeneity, and publication bias tests were represented as Pz, Ph, and Pe, respectively. Statistical significance was defined as P<0.05 for all analyses.Citation41

Results

Description of studies

A total of 211 English-language articles were obtained from SZGene and PubMed, and 14 Chinese-language articles were obtained from CNKI. After removing duplicate studies and those that did not meet our inclusion criteria, 41 articles were used in the meta-analysis (). Specifically, 28 articles addressed the 48 bp VNTR,Citation23,Citation42Citation68 nine articles involved the 12 bp TR,Citation23,Citation43,Citation48Citation50,Citation69Citation72 six articles pertained to the 120 bp TR,Citation18,Citation19,Citation65,Citation72Citation74 10 articles addressed the −521 C>T polymorphism,Citation18,Citation22Citation24,Citation58,Citation72Citation76 six articles referred to −616 C>G,Citation18,Citation23,Citation72,Citation74Citation76 and four articles entailed −376 C>T.Citation18,Citation23,Citation72,Citation75 Details of these studies are listed in . We omitted loci from our meta-analysis that were not represented in at least four articles.

Figure 1 Study selection process in this meta-analysis.

Abbreviations: CNKI, China National Knowledge Infrastructure; VNTR, variable number tandem repeat.
Figure 1 Study selection process in this meta-analysis.

Table 1 Characteristics of studies that qualified to be included in the meta-analysis

Results of data analysis

No association between the 48 bp VNTR and schizophrenia risk

Allele frequencies of the 48 bp VNTR are listed in . Results of pooled analyses are summarized in , and data from subgroup analyses are depicted in . We were unable to obtain specific data regarding the number of 7-repeat (7R) alleles in the 48 bp VNTR,Citation44 despite multiple attempts to contact the corresponding author. Thus, this study was omitted from our analysis of an association between 7R and schizophrenia risk. When we conducted a pooled analysis of the remaining 5,316 cases and 4,677 controls, we found that 7R was not associated with schizophrenia risk (Pz=0.349, OR =1.071, 95% CI =0.928–1.236) under a random effects model with a power of 0.271 ( and Figure S1).Citation35 No association was found in subgroup analysis by ethnicity (ie, Caucasian [Pz=0.238, OR =1.127, 95% CI =0.924–1.375], East Asian [Pz=0.901, OR =0.966, 95% CI =0.560–1.667], Indian [Pz=0.211, OR =0.772, 95% CI =0.514–1.158], Mestizos [Pz=0.310, OR =1.413, 95% CI =0.725–2.754], and Israeli [Pz=0.512, OR =1.164, 95% CI =0.739–1.835]). Moreover, no association of 7R with the risk of schizophrenia was ascertained in subgroup analysis by source of controls. No significant heterogeneity was found in the pooled or subgroup analyses.

Table 2 Allele frequency of 48 bp VNTR polymorphism

Table 3 Pooled associations of DRD4 polymorphisms and schizophrenia

Table 4 Subgroup associations of DRD4 polymorphisms with schizophrenia

To incorporate data from the study of Serretti et al,Citation44 the 48 bp VNTR was classified into S (short allele, ≤4 TRs) and L (long allele, ≥5 TRs) groups. In the study by Kohn et al,Citation43 the 48 bp VNTR data could not be categorized into S and L groups, so this study was omitted from the analysis. The remaining data comprised 5,637 cases and 5,074 controls ( and Figure S2). Results of a pooled analysis indicated no relationship between this polymorphism and schizophrenia risk (Pz=0.073, OR =1.135, 95% CI =0.988–1.303) with a power of 0.909. No association was found in the subgroup analysis by source of control or by ethnicity, except for Mestizos (Pz=0.048, OR =1.949, 95% CI =1.007–3.77). Significant heterogeneity was found in the pooled analysis (Pe=0.009, ICitation2=44%) and in the subgroup analysis by ethnicity in the East Asian subgroup (Pe=0.014, ICitation2=49.1%) and by source of control in the hospital-based subgroup (Pe=0.016, ICitation2 =59.2%).

No association between the 12 bp TR and schizophrenia risk

To evaluate the relationship between the 12 bp TR and the risk of schizophrenia, 1,517 cases and 1,746 controls were included ( and Figures S3–S7). Allele groups were defined as in (ie, inserted) and de (ie, deleted). In the dominant model,Citation34,Citation35 the pooled OR using a random effects model was 1.083 (Pz=0.377, 95% CI =0.907–1.293) with a power of 0.154 (). No association was found in subgroup analysis by ethnicity or by source of controls (). No significant heterogeneity was observed in the pooled or subgroup analyses.

Table 5 Genotype distribution and allele frequency of 12 bp TR

Genotype L/L of the 120 bp TR might be a risk factor for schizophrenia

In a random model, a pooled analysis was conducted (1,912 cases and 1,836 controls) to evaluate the relationship between genotype L/L of the 120 bp TR and schizophrenia risk ( and Figures S8–S12). In the recessive model,Citation34,Citation35 genotype L/L was found to be a potential risk factor for schizophrenia (Pz=0.004, OR =1.275, 95% CI =1.081–1.504) with a power of 0.959 (). Findings from subgroup analysis indicated significant associations in East Asian (Pz=0.002, OR =1.317, 95% CI =1.108–1.565) and hospital-based subgroups (Pz=0.002, OR =1.319, 95% CI =1.134–1.708) (). No association was found for the other subgroups, and no significant heterogeneity was ascertained in the pooled or subgroup analyses.

Table 6 Genotype distribution and allele frequency of 120 bp TR

The −521 CC variant might be a risk factor for schizophrenia

Pooled and subgroup analyses were performed in a random model with 2,927 cases and 2,938 controls ( and Figures S13–S17). In the recessive model, −521 CC was found to be a potential risk factor for schizophrenia in the pooled analysis (Pz=0.021, OR =1.177, 95% CI =1.024–1.353) with a power of 0.656 (). In subgroup analyses by ethnicity and source of controls, the association was only detected in the East Asian subgroup (Pz=0.009, OR =1.218, 95% CI =1.050–1.413) (). No significant heterogeneity was noted in the pooled or subgroup analyses.

Table 7 Genotype distribution and allele frequency of −521 C>T

No association between −616 C>G and the risk of schizophrenia

In a random model, pooled () and subgroup () analyses were performed with 1,735 cases and 1,724 controls ( and Figures S18–S22). Using the dominant model, results of the pooled analysis indicated a lack of an association between −616 C>G and schizophrenia risk (Pz=0.068, OR =1.133, 95% CI =0.991–1.295) with a power of 0.45. All cases and controls in this analysis corresponded to the East Asian subgroup. Findings from a subgroup analysis of source of controls showed no association. There was no significant heterogeneity in the pooled or subgroup analyses.

Table 8 Genotype distribution and allele frequency of −616 C>G

No association of the −376 C>T variant with schizophrenia

We assessed the relationship between the −376 C>T polymorphism and schizophrenia risk in pooled and subgroup analyses of 1,191 cases and 1,215 controls in a random model (, , and and Figures S23–S27). In the recessive model, −376 C>T was not associated with the risk of schizophrenia in a pooled analysis (Pz=0.117, OR =1.171, 95% CI =0.962–1.425) with a power of 0.357 (). No association was detected in subgroup analyses by ethnicity or source of controls (). No significant heterogeneity was ascertained in the pooled or subgroup analyses.

Table 9 Genotype distribution and allele frequency of −376 C>T

Sensitivity analysis

The results of sensitivity analyses showed that the combined ORs did not change significantly for meta-analyses in which each study was omitted singly. Thus, the results were considered stable and reasonable.

Publication bias

Potential publication bias was found in funnel plots in which the standard error of log(OR) of each study was plotted against its log(OR). No evidence of publication bias was found in pooled analyses ().

Figure 2 Funnel plot analysis for the detection of publication bias in the association between the 48 bp VNTR (7R vs others) and schizophrenia.

Abbreviations: OR, odds ratio; 7R, 7 repeat; VNTR, variable number tandem repeat.
Figure 2 Funnel plot analysis for the detection of publication bias in the association between the 48 bp VNTR (7R vs others) and schizophrenia.

Figure 3 Funnel plot analysis for the detection of publication bias in the association between 48 bp VNTR (L vs S) and schizophrenia.

Notes: L, long allele; S, short allele.
Abbreviations: OR, odds ratio; VNTR, variable number tandem repeat.
Figure 3 Funnel plot analysis for the detection of publication bias in the association between 48 bp VNTR (L vs S) and schizophrenia.

Figure 4 Funnel plot analysis for the detection of publication bias in the association between 12 bp TR and schizophrenia.

Abbreviations: OR, odds ratio; TR, tandem repeat.
Figure 4 Funnel plot analysis for the detection of publication bias in the association between 12 bp TR and schizophrenia.

Figure 5 Funnel plot analysis for the detection of publication bias in the association between 120 bp TR and schizophrenia.

Abbreviations: OR, odds ratio; TR, tandem repeat.
Figure 5 Funnel plot analysis for the detection of publication bias in the association between 120 bp TR and schizophrenia.

Figure 6 Funnel plot analysis for the detection of publication bias in the association between −521 C>T and schizophrenia.

Abbreviation: OR, odds ratio.
Figure 6 Funnel plot analysis for the detection of publication bias in the association between −521 C>T and schizophrenia.

Figure 7 Funnel plot analysis for the detection of publication bias in the association between −616 C>G and schizophrenia.

Abbreviation: OR, odds ratio.
Figure 7 Funnel plot analysis for the detection of publication bias in the association between −616 C>G and schizophrenia.

Figure 8 Funnel plot analysis for the detection of publication bias in the association between −376 C>T and schizophrenia.

Abbreviation: OR, odds ratio.
Figure 8 Funnel plot analysis for the detection of publication bias in the association between −376 C>T and schizophrenia.

Discussion

Results of other studies have associated the 7R polymorphism with ADHD in a meta-analysisCitation77 and with increased brain activity to unpleasant stimuli.Citation78 We sought to determine whether 7R was also associated with schizophrenia risk. Findings of our pooled and subgroup analyses indicated that 7R was not associated with the risk of schizophrenia. Similarly, we found that the 48 bp VNTR (classified into L and S groups) was not associated with schizophrenia risk in most of our pooled and subgroup analyses, which is consistent with previously published meta-analyses.Citation29,Citation30 Only in the Mestizos subgroup, an association was detected. Our literature search yielded one article addressing Mestizos patients, and this article had an insufficient sample size to verify this association. Hence, the utility of the 48 bp VNTR as a means to assess schizophrenia risk in the Mestizo population warrants additional investigation. Lung et alCitation28 demonstrated an association between the 48-bp VNTR and schizophrenia risk but noted that sample bias might have led to a false-positive result.Citation29

We determined that the L/L genotype of the 120 bp TR and the −521 CC variant might be risk factors for schizophrenia among East Asians; this relationship was not found in other populations. This discrepancy between East Asians and other populations might have resulted from the small sample sizes of the other ethnicity subgroups, the distinct genetic backgrounds, or different demographic or lifestyle factors within the subgroups. The statistical power for the pooled analysis of the 12 bp TR, the −616 C>G polymorphism, and the −376 C>T variant was low. Therefore, these results will need to be validated further. In a study of linkage disequilibrium (LD) of DRD4 that included 17 polymorphisms,Citation23 the authors found no LD between −521 T>C and 120 bp TR (rCitation2=0.00). For all pairs of −616 C>G, −376 C>T, 12 bp TR, and 48 bp VNTR, no significant LD was observed.

Multiple meta-analyses have been conducted to date on the association between DRD4 and schizophrenia. The current meta-analysis included some new studies, involved a large sample size, and had high statistical power. We addressed six loci in DRD4; no other meta-analysis involving four of these loci (12 bp TR, 120 bp TR, −616 C>G, and −376 C>T) has been carried out. Moreover, we conducted subgroup analysis by ethnicity and by source of controls and included data both from SZGene and the CNKI databases.

The results described herein should be interpreted with caution. The present study was limited by a lack of exact allele/genotype frequencies for some of the included articles, despite our efforts to acquire this information from the corresponding authors. Therefore, these articles were omitted from the meta-analysis. Second, controls in some of the articles did not conform to Hardy–Weinberg equilibrium because of sample bias. Third, case–control studies were included in this meta-analysis, but family-based studies were not.Citation77 The ability to exploit cosegregation of variants with disease within families helps distinguish causal from noncausal factors. Family-based studies are more powerful to detect risk factors of diseases.Citation79 Moreover, we did not address possible interactions between the six loci and epigenetic factors. An association between DRD4 and schizophrenia risk was detected based on case–control studies rather than on functional ones. Our results will need to be validated on a functional level.

Conclusion

The −521 CC variant and the L/L genotype of the 120-bp TR might be risk factors for schizophrenia. No association with schizophrenia was detected for the 48 bp VNTR, the 12 bp TR, −616 C>G, or −376 C>T. Our results may provide an informative reference for subsequent genome-wide association studies.

Acknowledgments

This study was supported by the National Natural Science Foundation of China (No 81601653) and the Doctoral Research Start Foundation of Liaoning Province (201601115) (both to Dr Jun Yao). The article was edited by native English-speaking experts of BioMed Proofreading, LLC.

Disclosure

The authors report no conflicts of interest in this work.

References

  • SullivanPFThe genetics of schizophreniaPLoS Med200527e21216033310
  • TsuangMTStoneWSFaraoneSVSchizophrenia: a review of genetic studiesHarv Rev Psychiatry19997418520710579099
  • WrayNRVisscherPMNarrowing the boundaries of the genetic architecture of schizophreniaSchizophr Bull2010361142319996148
  • CarlssonAThe current status of the dopamine hypothesis of schizophreniaNeuropsychopharmacology1988131791863075131
  • SitSYDopamine agonists in the treatment of Parkinson’s disease past, present and futureCurr Pharm Des20006121211124810903391
  • HowesOMcCutcheonRStoneJGlutamate and dopamine in schizophrenia: an update for the 21st centuryJ Psychopharmacol20152929711525586400
  • SeemanPGuanHCVan TolHHDopamine D4 receptors elevated in schizophreniaNature199336564454414458413587
  • SumiyoshiTStockmeierCAOverholserJCThompsonPAMeltzerHYDopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depressionBrain Res19956811–21091167552267
  • Van TolHHBunzowJRGuanHCCloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapineNature199135063196106141840645
  • MacciardiFPetronisAVan TolHHAnalysis of the D4 dopamine receptor gene variant in an Italian schizophrenia kindredArch Gen Psychiatry19945142882937909222
  • AllenNCBagadeSMcQueenMBSystematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene databaseNat Genet200840782783418583979
  • BertramLGenetic research in schizophrenia: new tools and future perspectivesSchizophr Bull200834580681218644854
  • AsghariVSanyalSBuchwaldtSPatersonAJovanovicVVan TolHHModulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variantsJ Neurochem1995653115711657643093
  • KornfeldRKornfeldSAssembly of asparagine-linked oligosaccharidesAnnu Rev Biochem1985546316643896128
  • D’SouzaUMRussCTahirEFunctional effects of a tandem duplication polymorphism in the 5′flanking region of the DRD4 geneBiol Psychiatry200456969169715522254
  • McCrackenJTSmalleySLMcGoughJJEvidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD)Mol Psychiatry20005553153611032387
  • MillJFisherNCurranSRichardsSTaylorEAshersonPPolymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorderNeuroreport200314111463146612960764
  • XingQHWuSNLinZGAssociation analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene in schizophreniaSchizophr Res200365191414623368
  • TsutsumiAGlattSJKanazawaTThe genetic validation of heterogeneity in schizophreniaBehav Brain Funct201174321981786
  • OkuyamaYIshiguroHNankaiMShibuyaHWatanabeAArinamiTIdentification of a polymorphism in the promoter region of DRD4 associated with the human novelty seeking personality traitMol Psychiatry200051646910673770
  • RonaiZSzekelyANemodaZAssociation between Novelty Seeking and the −521 C/T polymorphism in the promoter region of the DRD4 geneMol Psychiatry200161353811244482
  • OkuyamaYIshiguroHToruMArinamiTA genetic polymorphism in the promoter region of DRD4 associated with expression and schizophreniaBiochem Biophys Res Commun1999258229229510329380
  • MitsuyasuHKawasakiHNinomiyaHGenetic structure of the dopamine receptor D4 gene (DRD4) and lack of association with schizophrenia in Japanese patientsJ Psychiatr Res200741976377516887146
  • JonssonEGIvoRForslundKNo association between a promoter dopamine D(4) receptor gene variant and schizophreniaAm J Med Genet2001105652552811496369
  • MunafoMRFlintJMeta-analysis of genetic association studiesTrends Genet200420943944415313553
  • BarendregtJJDoiSALeeYYNormanREVosTMeta-analysis of prevalenceJ Epidemiol Community Health2013671197497823963506
  • LanaraZGiannopoulouEFullenMComparative study and meta-analysis of meta-analysis studies for the correlation of genomic markers with early cancer detectionHum Genomics2013711423738773
  • LungFWTzengDSShuBCEthnic heterogeneity in allele variation in the DRD4 gene in schizophreniaSchizophr Res2002572–323924512223255
  • GlattSJFaraoneSVTsuangMTSchizophrenia is not associated with DRD4 48-base-pair-repeat length or individual alleles: results of a meta-analysisBiol Psychiatry200354662963513129658
  • JonssonEGSedvallGCNothenMMCichonSDopamine D4 receptor gene (DRD4) variants and schizophrenia: meta-analysesSchizophr Res200361111111912648742
  • ShiJGershonESLiuCGenetic associations with schizophrenia: meta-analyses of 12 candidate genesSchizophr Res20081041–39610718715757
  • TerraccianoASutinARAnYPersonality and risk of Alzheimer’s disease: new data and meta-analysisAlzheimers Dement201410217918623706517
  • PalmerSCGardnerSTonelliMPhosphate-binding agents in adults with CKD: a network meta-analysis of randomized trialsAm J Kidney Dis201668569170227461851
  • PanYYaoJWangBAssociation of dopamine D1 receptor gene polymorphism with schizophrenia: a meta-analysisNeuropsychiatr Dis Treat2014101133113925018632
  • ThakkinstianAMcElduffPD’EsteCDuffyDAttiaJA method for meta-analysis of molecular association studiesStat Med20052491291130615568190
  • ZintzarasEIoannidisJPHeterogeneity testing in meta-analysis of genome searchesGenet Epidemiol200528212313715593093
  • HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
  • NaingCReidSAAungKComparing antibiotic treatment for leptospirosis using network meta-analysis: a tutorialBMC Infect Dis20171712928056834
  • DupontWDPlummerWDJrPower and sample size calculations for studies involving linear regressionControl Clin Trials19981965896019875838
  • XuFLDingMYaoJAssociation between mitochondrial DNA variations and schizophrenia in the northern Chinese Han populationPLoS One2017128e018276928846698
  • SedgwickPMarstonLHow to read a funnel plot in a meta-analysisBMJ2015351h471826377337
  • KaiserRKonnekerMHennekenMDopamine D4 receptor 48-bp repeat polymorphism: no association with response to antipsychotic treatment, but association with catatonic schizophreniaMol Psychiatry20005441842410889553
  • KohnYEbsteinRPHeresco-LevyUDopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjectsEur Neuropsychopharmacol19977139439088883
  • SerrettiALilliRLorenziCLattuadaESmeraldiEDRD4 exon 3 variants associated with delusional symptomatology in major psychoses: a study on 2,011 affected subjectsAm J Med Genet2001105328329011353451
  • HattoriENakajimaMYamadaKVariable number of tandem repeat polymorphisms of DRD4: re-evaluation of selection hypothesis and analysis of association with schizophreniaEur J Hum Genet200917679380119092778
  • TanakaTIgarashiSOnoderaOLack of association between dopamine D4 receptor gene and schizophreniaAm J Med Genet19956065805828825901
  • NankoSHattoriMIkedaKSasakiTKazamatsuriHKuwataSDopamine D4 receptor polymorphism and schizophreniaLancet19933418846689690
  • PetronisAMacciardiFAthanassiadesAAssociation study between the dopamine D4 receptor gene and schizophreniaAm J Med Genet19956054524558546161
  • OharaKNakamuraYXieDWPolymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophreniaBiol Psychiatry19964012120912178959285
  • AguirreAJApiquianRFresanACruz-FuentesCAssociation analysis of exon III and exon I polymorphisms of the dopamine D4 receptor locus in Mexican psychotic patientsPsychiatry Res2007153320921517822780
  • DanielsJWilliamsJMantRAshersonPMcGuffinPOwenMJRepeat length variation in the dopamine D4 receptor gene shows no evidence of association with schizophreniaAm J Med Genet19945432562587810584
  • SommerSSLindTJHestonLLSobellJLDopamine D4 receptor variants in unrelated schizophrenic cases and controlsAm J Med Genet199348290938103294
  • RaoPAPickarDGejmanPVRamAGershonESGelernterJAllelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapineArch Gen Psychiatry199451119129177944879
  • HongCJLeeYLSimCBHwuHGDopamine D4 receptor variants in Chinese sporadic and familial schizophrenicsAm J Med Genet19977444124159259377
  • JonssonEBreneSGeijerTA search for association between schizophrenia and dopamine-related allelesEur Arch Psychiatry Clin Neurosci199624662973048908411
  • RinettiGCamarenaBCruzCDopamine D4 receptor (DRD4) gene polymorphism in the first psychotic episodeArch Med Res2001321353811282178
  • FujiwaraYYamaguchiKTanakaYPolymorphism of dopamine receptors and transporter genes in neuropsychiatric diseasesEur Neurol199738Suppl 16109276194
  • LungFWChenNShuBCDopamine D4 receptor gene and the −521C>T polymorphism of the upstream region of the dopamine D4 receptor gene in schizophreniaPsychiatr Genet200616413914316829780
  • NakamuraMInoueAHemmiHSuzukiJPositive associations between dopamine D4 receptor polymorphism and schizophreniaEur Neuropsychopharmacol20066Suppl 3136136
  • LungFWShuBCKaoWTChenCNKuYCTzengDSAssociation of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control studyBMC Med Genet20091014720040103
  • FresanACamarenaBApiquianRAguilarAUrracaNNicoliniHAssociation study of MAO-A and DRD4 genes in schizophrenic patients with aggressive behaviorNeuropsychobiology2007553–417117517657171
  • ZhangMJianjunYYongchaoQXiaZYinpingHAssociation of schizophrenia with six candidate functional genesZhonghua Yi Xue Yi Chuan Xue Za Zhi2003201697112579508
  • ZhaoAZhiminXJindongCXiaogangCZheningLAssociation analysis of dopamine D4 receptor gene with quality traits and quantitative traits of schizophreniaChin J Psychiatry200538136
  • ZhaoAJinuoZJiaFYuhuZAssociation analysis of dopamine D4 gene and serotonin 2A receptor gene in schizophreniaChin J Behav Med Brain Sci20061510865867
  • ChenXJianhuaCWeidongJAssociation of DRD4 exon III gene polymorphism with attack behavior and psychiatric symptoms in patients with schizophreniaChin J Clin Med2016101826922695
  • LuZDongxiangWYipingQFeiLYeZAssociation analysis of dopamine DR4 receptor gene and apolipoprotein E gene in schizophreniaChin J Psychiatry20033611720
  • LiangKWThe association of DA2, DA3, and DA4 receptor gene polymorphology with schizophrenia also in medical jurisprudence and human genetics studiesdoctor’s thesisShenyangChina Medical University2005 Chinese
  • TangYZhuojiCRulunZChaofengZAssociation analysis of schizophrenia and dopamine D4 receptor gene polymorphismChin J Med Sci20018116995998
  • SerrettiALilliRDi BellaDDopamine receptor D4 gene is not associated with major psychosesAm J Med Genet199988548649110490704
  • HongCJChiuHJChangYSSimCBTwelve-nucleotide repeat polymorphism of D4 dopamine receptor gene in Chinese familial schizophrenic patientsBiol Psychiatry19984364324359532348
  • CatalanoMNobileMNovelliENothenMMSmeraldiEDistribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patientsBiol Psychiatry19933474594648268330
  • NakajimaMHattoriEYamadaKAssociation and synergistic interaction between promoter variants of the DRD4 gene in Japanese schizophrenicsJ Hum Genet2007521869117089069
  • PaiPArathilPKotambailAAssociation of GRIN1, ABCB1, and DRD4 genes and response to antipsychotic drug treatment in schizophreniaPsychiatr Genet201525313513625714447
  • LaiJHZhuYSHuoZHAssociation study of polymorphisms in the promoter region of DRD4 with schizophrenia, depression, and heroin addictionBrain Res2010135922723220801104
  • MitsuyasuHHirataNSakaiYAssociation analysis of polymorphisms in the upstream region of the human dopamine D4 receptor gene (DRD4) with schizophrenia and personality traitsJ Hum Genet2001461263111289715
  • ZhongHLiangPYongshengZJiePZhenghaoHAssociation of dopamine D4 receptor gene promoter region polymorphism with schizophreniaAdv Mod Biomed2010101132313234
  • SmithTFMeta-analysis of the heterogeneity in association of DRD4 7-repeat allele and AD/HD: stronger association with AD/HD combined typeAm J Med Genet B Neuropsychiatr Genet2010153B61189119920468072
  • GehrickeJGSwansonJMDuongSIncreased brain activity to unpleasant stimuli in individuals with the 7R allele of the DRD4 genePsychiatry Res20152311586325481571
  • YangZThomasDCTwo-stage family-based designs for sequencing studiesBMC Proc20148Suppl 1S3225519319